Abstract
* Remdesivir (Veklury) is the first antiviral drug approved to treat patients ages 12 and older who are hospitalized with COVID-19.
* The drug is administered via slow IV infusion.
* Elevated liver enzymes are common with treatment. Hypersensitivity reactions, including anaphylaxis, are possible.